This is up 3 cents from the 57 cents per share that it reported during the same time a year ago.
Advertisement
The world’s second-largest drugmaker benefited from surging sales for its newest drugs and key products that are slightly older.
During the quarter, Pfizer completed its $16 billion deal to buy its smaller rival, which has transformed New York-based Pfizer into a leading player in the emerging market for lower-priced versions of costly biotech drugs. In the latest quarter, new pneumonia medicine Prevnar 13 helped drive sales.
“Our research pipeline continues to advance with a focus on therapeutic areas of high unmet need”, said Pfizer chief executive Ian Read, adding that recent advances “could support the development of potential important new therapies to further strengthen our innovative products business”.
Its total revenue slipped 2 per cent to $12.09 billion, hurt in part by foreign exchange rates, but the top line also beat the average Street forecast of $11.49 billion.
Company’s net income dropped to $2.13 billion, or 34 cents for each share, within the third quarter, from $2.67 billion, or 42 cents for each reveal, last year.
PFE shares were up 2% as of Noon Tuesday.
Analysts predicted 51 cents in per-share profit on $US11.56 billion in sales, according to Thomson Reuters.
In addition to better-than-expected sales of certain drugs, somewhat lower research and development expenses helped drive the per-share earnings beat, noted Evercore ISI analyst Mark Schoenebaum.
The company increased its 2015 rage of revenue by earlier $1 billion to now $47.5 billion to $48.5 billion. “During third-quarter 2015, we were able to grow revenues by 4% operationally, excluding the impact of foreign exchange and legacy Hospira operations, despite the continued significant negative impact from product losses of exclusivity, primarily Celebrex and Zyvox in the USA and Lyrica in certain developed Europe markets”.
Looking ahead, the company raised its full-year earnings forecast to between the range of $2.16 to $2.20 a share, an increase from its previous outlook of $2.04 to $2.10 a share.
Advertisement
The company said research and development spending declined 4 per cent during the quarter.
